Literature DB >> 30150039

Value of [18F]FDG PET radiomic features and VEGF expression in predicting pelvic lymphatic metastasis and their potential relationship in early-stage cervical squamous cell carcinoma.

Kexin Li1, Hongzan Sun1, Zaiming Lu1, Jun Xin1, Le Zhang1, Yan Guo2, Qiyong Guo3.   

Abstract

PURPOSE: The purpose of this study was to explore the value of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography ([18F]FDG PET/CT) radiomic features combined with vascular endothelial growth factor (VEGF) expression in predicting pelvic lymphatic metastasis in patients with early-stage cervical squamous cell carcinoma and the added value of radiomic features in predicting VEGF expression.
MATERIALS AND METHODS: Ninety-four newly diagnosed cervical squamous cell carcinoma patients (training dataset: n = 64, validation cohort: n = 30) in stage Ia to IIa, according to the International Federation of Gynecology and Obstetrics (FIGO) staging system, who underwent [18F]FDG PET/CT were retrospectively analyzed. Radiomic features of the [18F]FDG PET scans were extracted, and the value of the lymph node sizes, metabolic parameters (both tumor and lymph nodes), radiomic features and VEGF expression level in predicting lymphatic metastasis were evaluated by receiver operating characteristics curves (ROC) and were compared using DeLong test. Moreover, we studied the associations between the [18F]FDG PET radiomic features and VEGF expression.
RESULTS: Total lesion glycolysis (TLG) and the expression of VEGF were significantly higher in subjects with lymphatic metastasis than in those without. The homogeneity feature derived from the histogram, the skewness, had a certain value in predicting lymphatic metastasis (AUC = 0.803 in training dataset, P < 0.05, 95% CI 0.684, 0.892; AUC = 0.757 in validation dataset, P < 0.05, 95% CI 0.545, 0.904). Additionally, the combination of this radiomic feature and VEGF expression had a significantly superior predictive value (AUC = 0.878, P < 0.05, 95% CI 0.772- 0.947), compared to that of the conventional parameters. Moreover, 26 radiomic features derived from the histogram and GLCM features correlated with VEGF expression.
CONCLUSIONS: In patients with early-stage cervical squamous cell carcinoma, PLN metastasis can be predicted by TLG and the textural feature of homogeneity. Radiomic features in combination with the VEGF expression level improved the prediction accuracy. In addition, some features derived from the histogram and gray-level co-occurrence matrices (GLCM) may have a certain value in predicting the VEGF expression level.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (18)F-fluorodeoxyglucose positron emission; Cervical squamous cell carcinomas; Intratumor heterogeneity; Lymphatic metastasis; Radiomics; Tomography

Mesh:

Substances:

Year:  2018        PMID: 30150039     DOI: 10.1016/j.ejrad.2018.07.024

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  16 in total

1.  AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics.

Authors:  Isabella Castiglioni; Francesca Gallivanone; Paolo Soda; Michele Avanzo; Joseph Stancanello; Marco Aiello; Matteo Interlenghi; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-11       Impact factor: 9.236

2.  Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data.

Authors:  Steven P Rowe; Lilja B Solnes; Yafu Yin; Grant Kitchen; Martin A Lodge; Nicolas A Karakatsanis; Arman Rahmim; Martin G Pomper; Jeffrey P Leal
Journal:  J Digit Imaging       Date:  2019-12       Impact factor: 4.056

3.  PET/MRI and PET/CT Radiomics in Primary Cervical Cancer: A Pilot Study on the Correlation of Pelvic PET, MRI, and CT Derived Image Features.

Authors:  Shadi A Esfahani; Angel Torrado-Carvajal; Barbara Juarez Amorim; David Groshar; Liran Domachevsky; Hanna Bernstine; Dan Stein; Debra Gervais; Onofrio A Catalano
Journal:  Mol Imaging Biol       Date:  2021-10-07       Impact factor: 3.488

Review 4.  Radiomics in Oncological PET Imaging: A Systematic Review-Part 2, Infradiaphragmatic Cancers, Blood Malignancies, Melanoma and Musculoskeletal Cancers.

Authors:  David Morland; Elizabeth Katherine Anna Triumbari; Luca Boldrini; Roberto Gatta; Daniele Pizzuto; Salvatore Annunziata
Journal:  Diagnostics (Basel)       Date:  2022-05-27

5.  Value of integrated PET-IVIM MR in assessing metastases in hypermetabolic pelvic lymph nodes in cervical cancer: a multi-parameter study.

Authors:  Chen Xu; Siyao Du; Siyu Zhang; Bo Wang; Chengyan Dong; Hongzan Sun
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

6.  A novel 2-deoxy-2-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT)-based nomogram to predict lymph node metastasis in early stage uterine cervical squamous cell cancer.

Authors:  Shuai Liu; Zheng Feng; Jiajia Zhang; Huijuan Ge; Xiaohua Wu; Shaoli Song
Journal:  Quant Imaging Med Surg       Date:  2021-01

7.  Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas.

Authors:  Zhiyan Sun; Yiming Li; Yinyan Wang; Xing Fan; Kaibin Xu; Kai Wang; Shaowu Li; Zhong Zhang; Tao Jiang; Xing Liu
Journal:  Cancer Imaging       Date:  2019-10-21       Impact factor: 3.909

Review 8.  Pathological angiogenesis and inflammation in tissues.

Authors:  Ji-Hak Jeong; Uttam Ojha; You Mie Lee
Journal:  Arch Pharm Res       Date:  2020-11-23       Impact factor: 4.946

9.  Self-Regulation of Cerebral Metabolism and Its Neuroprotective Effect After Hypoxic-Ischemic Injury: Evidence From 1H-MRS.

Authors:  Kexin Li; Yang Zheng; Xiaoming Wang
Journal:  Front Neuroanat       Date:  2021-06-17       Impact factor: 3.856

10.  Can computed tomography-based radiomics potentially discriminate between anterior mediastinal cysts and type B1 and B2 thymomas?

Authors:  Lulu Liu; Fangxiao Lu; Peipei Pang; Guoliang Shao
Journal:  Biomed Eng Online       Date:  2020-11-27       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.